Simplify Logo

Full-Time

Program Manager

Confirmed live in the last 24 hours

Abata Therapeutics

Abata Therapeutics

11-50 employees

Develops therapies for autoimmune diseases

Biotechnology

Senior, Expert

Belmont, MA, USA

Category
Lab & Research
Life Sciences
Required Skills
Management
Requirements
  • Bachelor’s degree or higher in Biology, Chemistry, Microbiology, Life Sciences, or an equivalent scientific discipline
  • 5+ years’ experience in Program Management or related function, across various stages of drug development, with proven track record of success managing multiple projects/priorities
  • Prior experience managing and working with cross-functional teams in a matrix environment
  • Prior experience in a consulting firm (BCG, etc.) is a plus
  • Travel: 0-10%
Responsibilities
  • Manage, optimize, track, and coordinate multiple workstreams across research, clinical, and technical operations to ensure key objectives and milestones are met
  • Build relationships and work cross-functionally with key stakeholders (Executive management, Program Team Leads, functional leads, external vendors and partners) to ensure alignment and drive execution of functional and program objectives
  • Identify critical path activities, resource constraints, risks, and conflicts that could impact timelines
  • Develop and optimize program management tools and processes to ensure consistency across functions and programs
  • Maintain a current overview of program status, and clearly and pro-actively communicate progress
  • Thought partner with Program Team Leads (PTLs) enabling strategic messaging and framing of key program outputs both internally and externally
  • Prepare presentation materials and participate in team discussions.

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Abata stands out in the biotech market by targeting a specific niche of autoimmune disease patients and forming strategic partnerships, such as with ElevateBio, to enhance their research and manufacturing capabilities. The company's goal is to transform treatment options for autoimmune diseases through advanced therapies.

Company Stage

Series A

Total Funding

$60.3M

Headquarters

Cambridge, Massachusetts

Founded

2021

Growth & Insights
Headcount

6 month growth

-2%

1 year growth

-5%

2 year growth

11%
Simplify Jobs

Simplify's Take

What believers are saying

  • The appointment of industry veterans like Leonard Dragone and Ellen Cahir-McFarland strengthens Abata's leadership team, enhancing its scientific and clinical capabilities.
  • With significant funding, including a recent $95 million equity investment, Abata is well-positioned to accelerate product development and expand its operations.
  • The company's collaborative and enthusiastic work environment, driven by a mission to transform autoimmune disease treatment, offers a fulfilling and impactful career.

What critics are saying

  • The highly specialized focus on Treg cell therapies may limit Abata's market reach and make it vulnerable to advancements by competitors in broader therapeutic areas.
  • Delays in clinical trials or regulatory approvals could hinder the timely commercialization of their lead product, ABA 201, impacting revenue and growth prospects.

What makes Abata Therapeutics unique

  • Abata Therapeutics leverages the unique biology of regulatory T cells (Tregs) to develop transformative therapies for autoimmune diseases, setting it apart from traditional biotech approaches.
  • Their strategic partnership with ElevateBio ensures scalable and regulatory-compliant manufacturing processes, a critical advantage in the competitive biotech landscape.
  • Focused on niche markets like type 1 diabetes and progressive multiple sclerosis, Abata addresses unmet medical needs with innovative Treg cell therapies.